



Live Healthy
in GLEIA



Creating a New Era
for Heart Failure
Management
by Utilizing
GLEIA[®]



Who we are?



Rapid testing of medical grade
for anyone, anywhere, anytime.



Business
Advisor

Matthew Frith



CFO

Y. Tsujii



Science
Advisor

E. Tamiya
Prof. of
The Univ. of Osaka



CEO

H. Sugihara
MBA



Medical
Advisor

Andrew Coats
CEO of
Heart Research Institute



COO

田中 伸幸



CTO

山村 航太郎
臨床検査技師



HF Pandemic



Heart Failure



65M

global
patient



50%

5-year
survival





\$28B

economic
burden

Tackling the Pandemic

HF biomarker informed care is essential.

HF biomarker
NT-proBNP




CV death

↓ 26%

Readmissions

↓ 44%



***Mobile-ready**


Optimizing
Treatment

Problem




BUT...

**NT-proBNP (10 pg/mL~)
requiring a hospital visit**



**Hospital visits are
a significant burden.**



**Poor visit adherence
and disease control.**

Solution



What if the Lab came home?



- Small
- Simple
- Affordable
- High-performance


Hospital @Home



Our Product



World smallest high-performance IVD.



Our Technology




Conventional

GLEIA[®]



Gold-Linked Electrochemical ImmunoAssay

Optical signal

Electric signal



Sensing reaction



Competitive Advantages



Lab analyzers

Mass
 $1/10,000$

GLEIA

Price
 $1/1,000$

Assay time
 $1/30$



10 patents GLB, Regulatory approved JP

Global Rollout



NT-proBNP Hospital@Home



2026 – 2027

2028 – 2032

2026
Launch

Clinical study

Launch

JP


SGP · AUS

EU · UK


USA

CHN · IND

MENA



APAC



2026

2027

2028

2029

2030

2031

2032

Live Healthy
in GLEIA



AI generated



Payer

\$28

Global average
Reimbursement price per test

Hospital

\$15

Selling price per test

IMMUNOSENS

Target COGS: \$2

Market & Sales



**Market
@2030**



H@H

 **17B+ USD**

**NA
2.4B**

**EU
2.1B**

**CN
3.9B**

**ME
1.0B**

**SA
2.4B**

**APAC
4.8B**

120M

Sales
Gross profit

Sales
117M USD
Gross profit
85M USD

4.0M
(2.7M)

31M
(22M)

2028


2030

2032

•45.9M prevalent HF patients across target markets in 2021
•Demographic ageing and prevalence adjustment → 57.8M by 2030 (~2.6% modeled CAGR)
•80% assumed to be managed at home → 46.2M addressable patients
•Monthly NT-proBNP testing → 554.8M tests annually •Volume-weighted average test price: ~\$30/test
•Annual retail-basis test-value TAM: ~\$16.6B •Sensor revenue sensitivity at \$23/test: ~\$12.8B annually
•Scope: EU + UK, APAC ex. Japan/China/India/Middle East, Japan, North America, China, India, Middle East, and South America.

Will cover

200 + items



Infections

AMR

Immunity

Emergency

Health promotion

Cardio-vascular

Endocrinology

Neurology

Mental health

Nursing care

Athlete conditioning

Oncology

Nephrology

Femtech

Anti-aging

Animal health

Items in orange are under development.



Let's Shape the Future Together !



 **IMMUNOSENS**

*Live Healthy
in GLEIA*